DDInter609 DDInter1376
Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL), that induce inflammatory and immunological reactions in several atopic or allergic conditions, such as eczema, allergic reaction, and rhinosinusitis. Dupilumab was generated by recombinant DNA technology in Chinese Hamster Ovary cell suspension culture. Dupilumab is commonly marketed as Dupixent, which is available as a formulation for subcutaneous injection. It was first approved by the FDA in 2017. It is currently used to treat atopic dermatitis, asthma as an add-on maintenance treatment, chronic rhinosinusitis with nasal polyposis, and eosinophilic es
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Dupilumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Dupilumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alemtuzumab
Dupilumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Dupilumab {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Dupilumab {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Dupilumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Dupilumab may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab
Dupilumab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Dupilumab may lead to a major life threatening interaction when taken with Fingolimod
Dupilumab may lead to a major life threatening interaction when taken with Upadacitinib